Biguanides, thiazolidinediones, secretagogues, and sodium-glucose cotransporter 2 (SGLT-2) inhibitors reduce the risk of AF recurrence, while glucagon-like peptide-1 (GLP-1) receptor agonists have a neutral effect on AF. This evidence concerns the gene GCG and atrial fibrillation.